Xizang Weixinkang Pharmaceutical Co (SHSE:603676) Other Current Liabilities: ¥4 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603676 Xizang Weixinkang Pharmaceutical Co Ltd SHSE:603676
79 GF Score
Price ¥9.33
GF Value ¥8.89
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Xizang Weixinkang Pharmaceutical Co Other Current Liabilities?

Xizang Weixinkang Pharmaceutical Co SHSE:603676 -3.01% 79 Other Current Liabilities is ¥4 Mil as of Mar. 2026. GuruFocus rates SHSE:603676 with a GF Score™ of 79/100 and a GF Value™ of ¥8.89 (Fairly Valued). The stock has 2 warning signs investors should review.

Xizang Weixinkang Pharmaceutical Co's other current liabilities for the quarter that ended in Mar. 2026 was ¥4 Mil.

Xizang Weixinkang Pharmaceutical Co's quarterly other current liabilities increased from Sep. 2025 (¥5 Mil) to Dec. 2025 (¥7 Mil) but then declined from Dec. 2025 (¥7 Mil) to Mar. 2026 (¥4 Mil).

Xizang Weixinkang Pharmaceutical Co's annual other current liabilities increased from Dec. 2023 (¥5 Mil) to Dec. 2024 (¥8 Mil) but then declined from Dec. 2024 (¥8 Mil) to Dec. 2025 (¥7 Mil).

Xizang Weixinkang Pharmaceutical Co Other Current Liabilities Related Terms

Xizang Weixinkang Pharmaceutical Co Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Xizang Weixinkang Pharmaceutical Co's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xizang Weixinkang Pharmaceutical Co Other Current Liabilities Chart

Xizang Weixinkang Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.69 7.36 4.95 8.18 7.23

Xizang Weixinkang Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.29 3.58 4.52 7.23 3.64
SHSE:603676
79GF Score
Xizang Weixinkang Pharmaceutical Co Ltd SHSE:603676
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xizang Weixinkang Pharmaceutical Co Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of ¥4 Mil mean?
Xizang Weixinkang Pharmaceutical Co (SHSE:603676) has a Other Current Liabilities of ¥4 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Xizang Weixinkang Pharmaceutical Co.
Is Xizang Weixinkang Pharmaceutical Co's Other Current Liabilities too high?
Xizang Weixinkang Pharmaceutical Co's current Other Current Liabilities is ¥4 Mil. Overall, Xizang Weixinkang Pharmaceutical Co has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Xizang Weixinkang Pharmaceutical Co's Other Current Liabilities compare to ZTS?
Xizang Weixinkang Pharmaceutical Co's Other Current Liabilities of ¥4 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Xizang Weixinkang Pharmaceutical Co. Xizang Weixinkang Pharmaceutical Co's current Other Current Liabilities is ¥4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xizang Weixinkang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Xizang Weixinkang Pharmaceutical Co (SHSE:603676) is currently considered Fairly Valued. The stock's GF Value™ is ¥8.89, compared to a current price of ¥9.33 — trading 4.9% above its estimated fair value. The current Other Current Liabilities is ¥4 Mil. Xizang Weixinkang Pharmaceutical Co's overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Xizang Weixinkang Pharmaceutical Co (SHSE:603676), the current Other Current Liabilities is ¥4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xizang Weixinkang Pharmaceutical Co (SHSE:603676) Overvalued in 2026?

Based on GuruFocus' analysis, Xizang Weixinkang Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥9.33 is trading 4.9% above its estimated GF Value™ of ¥8.89. GuruFocus considers Xizang Weixinkang Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:603676:

  • Other Current Liabilities: ¥4 Mil
  • GF Value™: ¥8.89 vs. price of ¥9.33 (4.9% above fair value)
  • GF Score™: 79/100 with 2 warning signs

No single metric tells the full story. See the SHSE:603676 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xizang Weixinkang Pharmaceutical Co Business Description

Address Yuanqu South Road, 3rd Floor, Building 4, Industrial Center, No. 5, Zone B, Lhasa Economic and Technological, Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Xizang Weixinkang Pharmaceutical Co Ltd is engaged in research & development, production and sales of chemical pharmaceutical preparations and their raw materials. It also produces and sells liver protection drugs and antibiotic products.
79GF Score

Get the complete analysis for SHSE:603676

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥9.33
Price
¥8.89
GF Value